Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Synta Pharmaceuticals Corp.
This is an open-label Phase 1 dose-escalation study in patients with solid tumors treated with STA-9090 (ganetespib) to evaluate for safety, tolerance and efficacy.
Age
25–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must be documented to be refractory or not candidates for current approved therapies. - Must have anECOG status 0-2. - Peripheral neuropathy ?2.
Must have acceptable organ and marrow function per protocol parameters.
No clinically significant ventricular arrythmias or ischemia.
You may not be if
Must not be pregnant or breastfeeding. -No chemotherapy or radiation within 3 weeks..
No previous radiation to \>25% of total bone marrow.
No previous high dose chemotherapy with autologous or allogeniec hematopoietic stem cell transplantation.
No primary brain tumors or active brain metastases.
No use of any investigational agents within 4 weeks.
No treatment with chronic immunosuppressants.
No uncontrolled, intercurrent illness.
Clareo Health | Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
